Compare MFIC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | NBTX |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2018 |
| Metric | MFIC | NBTX |
|---|---|---|
| Price | $10.32 | $32.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $11.46 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 1.2M | 39.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.73 |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $2.99 |
| 52 Week High | $13.51 | $41.89 |
| Indicator | MFIC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 57.18 |
| Support Level | $9.48 | $20.11 |
| Resistance Level | $11.74 | N/A |
| Average True Range (ATR) | 0.40 | 2.69 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 57.09 | 47.72 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.